Endoscopic scoring systems for inflammatory bowel disease: Pros and cons

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 5, 2014, Pages 543-554

  Tontini, Gian Eugenio ^a,b   Bisschops, Raf ^c   Neumann, Helmut ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Advanced endoscopic imaging; Colonoscopy; Crohn's disease; Disease activity indices; Endoscopic disease activity; Inflammatory bowel disease; Mucosal activity; Mucosal healing; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE;

BARON SCORE; BLEEDING; CORRELATION COEFFICIENT; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CROHN DISEASE ENDOSCOPIC INDEX OF SEVERITY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOSCOPIC SCORING SYSTEM; ENDOSCOPIST; ENDOSCOPY; ERYTHEMA; FEASIBILITY STUDY; GOLD STANDARD; HEALING; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INTERMETHOD COMPARISON; MAYO ENDOSCOPIC SUBSCORE; MAYO SCORE; MEDICAL SPECIALIST; MICROSCOPY; MODIFIED BARON SCORE; MUCOSAL HEALING; OBSERVER VARIATION; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; POST HOC ANALYSIS; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RACHMILEWITZ ENDOSCOPIC INDEX; RATING SCALE; RELIABILITY; REMISSION; REPRODUCIBILITY; REVIEW; RUTGEERTS SCORE; SCORING SYSTEM; SIMPLE ENDOSCOPIC SCORE FOR CROHN DISEASE; SMALL BOWEL CAPSULE ENDOSCOPY; SMALL BOWEL ENDOSCOPIC SCORE; TRAINING; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE; ULCER; ULCERATIVE COLITIS; ULCERATIVE COLITIS COLONOSCOPIC INDEX OF SEVERITY; ULCERATIVE COLITIS ENDOSCOPIC INDEX OF SEVERITY; VALIDATION PROCESS; COLITIS, ULCERATIVE; GASTROINTESTINAL ENDOSCOPY; INTESTINE MUCOSA; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WOUND HEALING;

COLITIS, ULCERATIVE; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INTESTINAL MUCOSA; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WOUND HEALING;

EID: 84903135474     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.899899     Document Type: Review

References (114)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1): 46Y54
2. Burisch J, Jess T, Martinato M, Lakatos PL; ECCO YEpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7(4):322Y37
3. Pastorelli L, De Salvo C, Mercado JR, et al. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: Lessons learned from animal models and human genetics. Front Immunol 2013;4:280
4. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7(12):982Y1018
5. Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011;5(5): 484Y98
6. D'Haens G, Feagan B, Colombel JF, et al. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology 2012;143(6):1461Y9
7. Orlando A, Guglielmi FW, Cottone M, et al. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. Dig Liver Dis 2013;45(12):986Y91
8. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: A systematic review. Gut 2012;61(11):1619Y35
9. Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study. Inflamm Bowel Dis 2012;18(6):1006Y10
10. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved longYterm clinical outcomes in ulcerative colitis. Gastroenterology 2011;141(4):1194Y201
11. Frøslie KF, Jahnsen J, Moum BA, Vatn MH. IBSEN Group. Mucosal healing in inflammatory bowel disease: Results from a Norwegian populationYbased cohort. Gastroenterology 2007;133(2):412Y22
12. Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: A proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
13. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132(2):763Y86
14. Travis SP, Higgins PD, Orchard T, et al. Review article: Defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34(2):113Y24
15. Mazzuoli S, Guglielmi FW, Antonelli E, et al. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis 2013;45(12):969Y77
16. Pineton De Chambrun G, PeyrinYBiroulet L, Le'mann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7(1):15Y29
17. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2(4947): 1041Y8
18. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30(7):983Y9
19. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SESYCD. Gastrointest Endosc 2004;60(4):505Y12
20. Sostegni R, Daperno M, Scaglione N, et al. Review article: Crohn's disease: Monitoring disease activity. Aliment Pharmacol Ther 2003;17(Suppl 2):11Y17
21. Walsh AJ, Ghosh A, Brain AO, et al. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis 2013. [Epub ahead of print]
22. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61(4): 535Y42
23. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145(1):149Y57
24. Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013;11(1): 49Y54
25. Cooney RM, Warren BF, Altman DG, et al. Outcome measurement in clinical trials for Ulcerative Colitis: Towards standardisation. Trials 2007;8:17
26. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011;60(6):780Y7
27. Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013;145(5): 987Y95
28. Osada T, Ohkusa T, Yokoyama T, et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: InterY and intraobserver consistency. Inflamm Bowel Dis 2010;16(2):192Y7
29. Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn's disease activity: Comparison of the CDEIS and the SESYCD. Inflamm Bowel Dis 2010;16(12):2131Y6
30. Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62(2):201Y8
31. Colombel JF, Sandborn WJ, Allez M, et al. Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2014; 12(3):423Y31.e1
32. Louis E, Mary JY, VernierYMassouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142(1):63Y70
33. Lémann M, Mary JY, Colombel JF, et al. A randomized, doubleYblind, controlled withdrawal trial in Crohn's disease patients in longYterm remission on azathioprine. Gastroenterology 2005;128(7): 1812Y18
34. Reinisch W, Rutgeerts P, Panaccione R, et al. Identifying appropriate dichotomizing points for SESYCD to predict longYterm clinical remission for adalimumabtreated patients with Crohn's disease. J Crohns Colitis 2010;4(1):S31YP045
35. Moskovitz DN, Daperno M, Van assche G, et al. Defining and Validating CutYOff's for the Simple Endoscopic Score for Crohn's Disease. Gastroenterology 2007;132(4): A173YS1097
36. Ferrante M, Colombel JF, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013;145(5):978Y86
37. Ferrante M, Noman M, Vermeire S, et al. Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology 2010;138:S358
38. van Der Woude CJ, Stokkers P, van Bodegraven AA, et al. Phase I, doubleYblind, randomized, placebocontrolled, doseYescalation study of NIY0401 (a fully human antiYCD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. Inflamm Bowel Dis 2010;16(10):1708Y16
39. Mary JY, Lemann M, Colombel JF, et al. Endoscopic remission and response in Crohn's disease: An objective definition using the CDEIS. Gut 2005;54:A50
40. Colombel JF, Lemann M, Bouhnik Y, et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: First results of the Music clinical trials. Gastroenterology 2010;138: S166
41. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial. Gastroenterology 2012;142:1102Y11
42. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122(2): 512Y30
43. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25(6):665Y72
44. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99(4):956Y63
45. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004;127(3):730Y40
46. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6Ymercaptopurine, mesalamine, or placebo: A 2Yyear trial. Gastroenterology 2004;127(3):723Y9
47. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial. Gut 2006;55(6):842Y7
48. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: Efficacy and safety results of a randomised, doubleYblind, doubleYdummy, multicentre trial. Gut 2010; 59(6):752Y9
49. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5Yaminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317(26):1625Y9
50. Osada T, Ohkusa T, Yokoyama T, et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: InterY and intraobserver consistency. Inflamm Bowel Dis 2010;16(2):192Y7
51. Baron JH, Connell AM, LennardYJones JE. Variation between observers in Describing mucosal appearances in proctocolitis. Br Med J 1964;1(5375):89Y92
52. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352(24): 2499Y507
53. Rachmilewitz D. Coated mesalazine (5Yaminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 1989;298:82Y6
54. Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012;18(9):1634Y40
55. Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderateYtoYsevere ulcerative colitis. Gastroenterology 2012;142(2):257Y65
56. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9(6):483Y9
57. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98(4): 811Y18
58. PeyrinYBiroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, CYreactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63(1):88Y95
59. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between Disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6(11):1218Y24
60. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with earlyYstage Crohn's disease. Gastroenterology 2010; 138(2):463Y8
61. Thia K, Faubion WA Jr, Loftus et al. Short CDAI: Development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis 2011; 17(1):105Y11
62. Sandborn WJ. How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease. Dig Dis 2009;27(Suppl 1):80Y4
63. Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndromeYtype symptoms in patients with inflammatory bowel disease: A real association or reflection of occult inflammation?. Am J Gastroenterol 2010;105(8):788, 1789Y94
64. Knowles SR, Wilson JL, Connell WR, Kamm MA. Preliminary examination of the relations between Disease activity, illness perceptions, coping strategies, and psychological morbidity in Crohn's disease guided by the common sense model of illness. Inflamm Bowel Dis 2011;17(12): 2551Y7
65. Papi C, FascìYSpurio F, Rogai F, et al. Mucosal healing in inflammatory bowel disease: Treatment efficacy and predictive factors. Dig Liver Dis 2013;45(12):978Y85
66. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140(6):1817Y26
67. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18(12): 2218Y24
68. Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2013;19(5):1043Y52
69. Saibeni S, Rondonotti E, Iozzelli A, et al. Imaging of the small bowel in Crohn's disease: A review of old and new techniques. World J Gastroenterol 2007;13(24):3279Y87
70. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidenceYbased consensus guidelines. J Crohns Colitis 2013;7(7): 556Y85
71. Panés J, Bouzas R, Chaparro M, et al. Systematic review: The use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011;34(2): 125Y45
72. Rimola J, Ordás I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: Validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011;17(8):1759Y68
73. Ordás I, Rimola J, GarcíaYBosch O, et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: A prospective study. Gut 2013;62(11): 1566Y72
74. Calabrese E, Zorzi F, Onali S, et al. Accuracy of smallYintestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease. Clin Gastroenterol Hepatol 2013;11(8): 950Y5
75. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab Induces Deep Remission in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2014;12(3):414Y22. e5
76. Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: A proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
77. Rogler G, Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: What does it mean?. World J Gastroenterol 2013;19(43):7552Y60
78. Peyrin Y. Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5(5):477Y83
79. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longYterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15(9):1295Y301
80. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383Y95
81. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63(3):433Y42
82. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: Endoscopic appearances help predict cancer risk. Gut 2004;53(12): 1813Y16
83. Yokoyama K, Kobayashi K, Mukae M, et al. Clinical study of the relation between mucosal healing and longYterm outcomes in ulcerative colitis. Gastroenterol Res Pract 2013;2013:192794
84. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462Y76
85. Neumann H, Neurath MF. Ulcerative colitis: UCCIS - A reproducible tool to assess mucosal healing. Nat Rev Gastroenterol Hepatol 2012;9(12):692Y4
86. PeyrinY Biroulet L, Bressenot A, Kampman W. Histologic remission: The ultimate therapeutic goal in ulcerative colitis?. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
87. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013;7(10):827Y51
88. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: What does it mean?. Gut 1991;32(2):174Y8
89. Mathy C, Schneider K, Chen YY, et al. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003;9(6):351Y5
90. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126(2):451Y9
91. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: A caseYcontrol study. Clin Gastroenterol Hepatol 2013;11(12):1601Y8
92. Gurudu SR, Leighton JA. Correlation of two capsule endoscopy scoring systems with fecal calprotectin: Does it really matter?. Dig Dis Sci 2012;57:827Y9
93. Bourreille A, Ignjatovic A, Aabakken L, et al. Role of smallYbowel endoscopy in the management of patients with inflammatory bowel disease: An international OMEDYECCO consensus. Endoscopy 2009;41(7):618Y37
94. Tontini GE, Vecchi M, Neurath MF, Neumann H. Advanced endoscopic imaging techniques in Crohn's disease. J Crohns Colitis 2013. [Epub ahead of print]
95. Mow WS, Lo SK, Targan SR, et al. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2(1):31Y40
96. Gal E, Geller A, Fraser G, et al. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig Dis Sci 2008;53(7):1933Y7
97. Niv Y, Ilani S, Levi Z, et al. Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Niv score): A multicenter prospective study. Endoscopy 2012;44(1):21Y6
98. Gralnek IM, Defranchis R, Seidman E, et al. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2008;27(2):146Y54
99. Rosa B, Moreira MJ, Rebelo A, Cotter J. Lewis Score: A useful clinical tool for patients with suspected Crohn's Disease submitted to capsule endoscopy. J Crohns Colitis 2012;6(6):692Y7
100. Swaminath A, Legnani P, Kornbluth A. Video capsule endoscopy in inflammatory bowel disease: Past, present, and future redux. Inflamm Bowel Dis 2010;16(7): 1254Y62
101. Tontini GE, Vecchi M, Neurath MF, Neumann H. Endoscopic optical enhancement technologies in IBD. EMJ Gastroenterol 2013;1:54Y61
102. Khanna R, Levesque BG, Sandborn WJ. IBD: Measuring what countsYendoscopic assessment in IBD. Nat Rev Gastroenterol Hepatol 2014;11(1):9Y10
103. Iacucci M, Panaccione R, Ghosh S. Advances in novel diagnostic endoscopic imaging techniques in inflammatory bowel disease. Inflamm Bowel Dis 2013;19(4): 873Y80
104. Neumann H, Mönkemüller K, Neurath MF, et al. Advanced endoscopic imaging. Diagn Ther Endosc 2013;2013:206839
105. Neumann H, Vieth M, Günther C, et al. Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: A randomized controlled study. Inflamm Bowel Dis 2013; 19(9):1935Y42
106. Tontini GE, Vecchi M, Neurath MF, Neumann H. Review article: Newer optical and digital chromoendoscopy techniques vs. dyeYbased chromoendoscopy for diagnosis and surveillance in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38(10):1198Y208
107. Nishio Y, Ando T, Maeda O, et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006;55(12):1768Y73
108. Liu J, Dlugosz A, Neumann H. Beyond white light endoscopy: The role of optical biopsy in inflammatory bowel disease. World J Gastroenterol 2013;19(43):7544Y51
109. Buda A, Hatem G, Neumann H, et al. Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: A pilot study. J Crohns Colitis 2013. [Epub ahead of print]
110. Neumann H, Kiesslich R, Wallace MB, Neurath MF. Confocal laser endomicroscopy: Technical advances and clinical applications. Gastroenterology 2010; 139(2):388Y92
111. Neumann H, Kiesslich R. Endomicroscopy and endocytoscopy in IBD. Gastrointest Endosc Clin N Am 2013;23(3):695Y705
112. Neumann H, Vieth M, Atreya R, et al. Assessment of Crohn's disease activity by confocal laser endomicroscopy. Inflamm Bowel Dis 2012;18(12):2261Y9
113. Li CQ, Xie XJ, Yu T, et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol 2010;105(6):1391Y6
114. Kiesslich R, Duckworth CA, Moussata D, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012;61(8):1146Y53.